FDx Advisors Inc. Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

FDx Advisors Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 5.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,839 shares of the biopharmaceutical company’s stock after selling 310 shares during the period. FDx Advisors Inc.’s holdings in Gilead Sciences were worth $428,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Altfest L J & Co. Inc. bought a new position in Gilead Sciences in the 4th quarter worth approximately $210,000. Federated Hermes Inc. boosted its position in shares of Gilead Sciences by 4.9% during the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after acquiring an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Gilead Sciences by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $74,000. Finally, Eagle Asset Management Inc. lifted its position in Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after purchasing an additional 60,697 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.4 %

GILD traded up $0.96 during trading on Thursday, reaching $69.71. The stock had a trading volume of 3,754,162 shares, compared to its average volume of 7,471,450. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $86.85 billion, a price-to-earnings ratio of 192.25, a P/E/G ratio of 2.87 and a beta of 0.18. The stock’s 50 day moving average is $66.23 and its two-hundred day moving average is $71.88. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company posted $1.37 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.42%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.29% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Robert W. Baird reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a report on Wednesday, April 24th. UBS Group lowered their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research report on Monday, July 1st. Twelve research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $84.00.

Check Out Our Latest Stock Report on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.